<DOC>
	<DOC>NCT01881126</DOC>
	<brief_summary>This efficacy and safety study will evaluate LUMIGAN® RC/ LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL MALEATE-EX, 0.5%/TIMOLOL GFS 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.</brief_summary>
	<brief_title>An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<criteria>Ocular hypertension or glaucoma that requires treatment with medication Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes History of LASIK, LASEK, RK, and/or PRK in the study eye(s) History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>